Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results

Delivers solid results; adjusts full-year guidance in an increasingly challenging market

Highlights:

• Revenue of $1.72 billion represents 6.8% reported growth year-over-year; and up 9.5% on a core⁽¹⁾ basis.
• GAAP net income of $302 million with earnings per share (EPS) of $1.02, up 12% from the second quarter of 2022.
• Non-GAAP⁽²⁾ net income of $377 million with EPS of $1.27, up 12% from the second quarter of 2022.
• Full-year revenue is now expected to be in the range of $6.93 billion to $7.03 billion, representing reported growth of 1.2% to 2.7% and core⁽¹⁾ growth of 3.0% to 4.5%. Fiscal year 2023 non-GAAP⁽³⁾ EPS is now estimated to be in the range of $5.60 to $5.65.
• Third-quarter revenue is expected to be in the range of $1.640 billion to $1.675 billion with non-GAAP⁽³⁾ EPS of $1.36 to $1.38.

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.72 billion for the second quarter ended April 30, 2023, an increase of 6.8% compared to the second quarter of 2022 and up 9.5% on a core⁽¹⁾ basis.

Second-quarter GAAP net income was $302 million, or $1.02 per share. This compares with $274 million, or 91 cents per share, in the second quarter of fiscal year 2022. Non-GAAP⁽²⁾ net income was $377 million, or $1.27 per share during the quarter, compared with $340 million or $1.13 per share during the second quarter a year ago.

“In an increasingly challenging market environment, the Agilent team delivered solid results in the second quarter,” said Agilent President and CEO Mike McMullen. “Revenues of $1.72 billion are up 9.5 percent core⁽¹⁾ with growth across all end markets and regions. Our results are driven by an innovative and broad portfolio, a differentiated customer experience, and outstanding execution.”

Financial Highlights

Life Sciences and Applied Markets Group

Agilent’s Life Sciences and Applied Markets Group (LSAG) reported second-quarter revenue of $968 million, a year-over-year increase of 8% (up 10% on a core⁽¹⁾ basis). LSAG’s operating margin for the quarter was 27.3%.

Agilent CrossLab Group

The Agilent CrossLab Group (ACG) reported second-quarter revenue of $387 million, a year-over-year increase of 10% (up 13% on a core⁽¹⁾ basis). ACG’s operating margin for the quarter was 26.6%.

Diagnostics and Genomics Group

The Diagnostics and Genomics Group (DGG) reported second-quarter revenue of $362 million, a year-over-year increase of 1% (up 3% on a core⁽¹⁾ basis). DGG’s operating margin for the quarter was 20.2%.

Full Year and Third-Quarter Outlook

Reflecting increased market uncertainties, full-year revenue is now expected to be in the range of $6.93 billion to $7.03 billion, representing reported growth of 1.2% to 2.7% and core⁽¹⁾ growth of 3.0% to 4.5%. Fiscal year 2023 non-GAAP⁽³⁾ EPS guidance is now estimated to be in the range of $5.60 to $5.65.

The outlook for third-quarter revenue is expected to be in a range of $1.640 billion to $1.675 billion. Third-quarter non-GAAP⁽³⁾ earnings guidance is expected to be in the range of $1.36 to $1.38 per share.

The outlook is based on forecasted currency exchange rates.

Conference Call

Agilent’s management will present additional details regarding the company’s second-quarter 2023 financial results on a conference call with investors today at 1:30 p.m. PDT. This event will be broadcast live online in listen-only mode. To listen to the webcast, select the “Q2 2023 Agilent Technologies Inc. Earnings Conference Call” link on the Agilent Investor Relations website. The webcast will remain on the company site for 90 days.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Forward-Looking Statements

This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, information regarding Agilent’s growth prospects, business, financial results, revenue, and non-GAAP earnings guidance for Q3 and fiscal year 2023 and future amortization of intangibles. These forward-looking statements involve risks and uncertainties that could cause Agilent’s results to differ materially from management’s current expectations. Such risks and uncertainties include, but are not limited to, unforeseen changes in the strength of Agilent’s customers’ businesses; unforeseen changes in the demand for current and new products, technologies, and services; unforeseen changes in the currency markets; customer purchasing decisions and timing; and the risk that Agilent is not able to realize the savings expected from integration and restructuring activities. In addition, other risks that Agilent faces in running its operations include the ability to execute successfully through business cycles; the ability to meet and achieve the benefits of its cost-reduction goals and otherwise successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross-margin pressures; the risk that its cost-cutting initiatives will impair its ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties and global economic conditions on its operations, its markets and its ability to conduct business; the ability to improve asset performance to adapt to changes in demand; the ability of its supply chain to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix; the ability of Agilent to successfully integrate recent acquisitions; the ability of Agilent to successfully comply with certain complex regulations; and other risks detailed in Agilent’s filings with the Securities and Exchange Commission, including its quarterly report on Form 10-Q for the fiscal quarter ended January 31, 2023. Forward-looking statements are based on the beliefs and assumptions of Agilent’s management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.

(1) Core revenue growth excludes the impact of currency and acquisitions and divestitures within the past 12 months. Core revenue is a non-GAAP measure. Reconciliations between GAAP revenue and core revenue for Q2 fiscal year 2023 are set forth on page 6 of the attached tables along with additional information regarding the use of this non-GAAP measure. Core revenue growth rate as projected for Q3 fiscal year 2023 and full fiscal year 2023 excludes the impact of currency and acquisitions and divestitures within the past 12 months. Most of the excluded amounts pertain to events that have not yet occurred and are not currently possible to estimate with a reasonable degree of accuracy and could differ materially. Therefore, no reconciliation to GAAP amounts has been provided for the projection.

(2) Non-GAAP net income and non-GAAP earnings per share primarily exclude the impacts of intangibles amortization, transformational initiatives, acquisition and integration costs and net loss on equity securities. Agilent also excludes any tax benefits or expenses that are not directly related to ongoing operations, and which are either isolated or are not expected to occur again with any regularity or predictability. A reconciliation between non-GAAP net income and GAAP net income is set forth on page 4 of the attached tables along with additional information regarding the use of this non-GAAP measure.

(3) Non-GAAP earnings per share as projected for Q3 fiscal year 2023 and full fiscal year 2023 exclude primarily the estimated impacts of non-cash intangibles amortization, transformational initiatives, and acquisition and integration costs. Agilent also excludes any tax benefits or expenses that are not directly related to ongoing operations, and which are either isolated or are not expected to occur again with any regularity or predictability. Most of these excluded amounts pertain to events that have not yet occurred and are not currently possible to estimate with a reasonable degree of accuracy and could differ materially. Therefore, no reconciliation to GAAP amounts has been provided. Future amortization of intangibles is expected to be approximately $38 million per quarter.

AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(In millions, except per share amounts)
(Unaudited)
PRELIMINARY
	Three Months Ended								Six Months Ended
	April 30,								April 30,
	2023				2022				2023				2022
Net revenue	$	1,717			$	1,607			$	3,473			$	3,281
Costs and expenses:
Cost of products and services		793				746				1,581				1,510
Research and development		126				115				249				232
Selling, general and administrative		415				386				834				803
Total costs and expenses		1,334				1,247				2,664				2,545
Income from operations		383				360				809				736
Interest income		12				1				21				2
Interest expense		(24	)			(21	)			(49	)			(42	)
Other income (expense), net		6				(7	)			6				(44	)
Income before taxes		377				333				787				652
Provision for income taxes		75				59				133				95
Net income	$	302			$	274			$	654			$	557
Net income per share:
Basic	$	1.02			$	0.92			$	2.21			$	1.86
Diluted	$	1.02			$	0.91			$	2.20			$	1.84
Weighted average shares used in computing net income per share:
Basic		296				299				296				300
Diluted		297				301				297				302
The preliminary income statement is estimated based on our current information.
Page 1

AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEET
(In millions, except par value and share amounts)
(Unaudited)
PRELIMINARY
				April 30,				October 31,
				2023				2022
ASSETS
Current assets:
	Cash and cash equivalents			$	1,175			$	1,053
	Accounts receivable, net				1,401				1,405
	Inventory				1,103				1,038
	Other current assets				270				282
		Total current assets			3,949				3,778
Property, plant and equipment, net					1,184				1,100
Goodwill					3,980				3,952
Other intangible assets, net					798				821
Long-term investments					186				195
Other assets					695				686
		Total assets		$	10,792			$	10,532
LIABILITIES AND EQUITY
Current liabilities:
	Accounts payable			$	479			$	580
	Employee compensation and benefits				359				455
	Deferred revenue				519				461
	Short-term debt				—				36
	Other accrued liabilities				309				329
		Total current liabilities			1,666				1,861
Long-term debt					2,733				2,733
Retirement and post-retirement benefits					97				97
Other long-term liabilities					515				536
		Total liabilities			5,011				5,227
Total Equity:
	Stockholders' equity:
	Preferred stock; $0.01 par value; 125 million
		shares authorized; none issued and outstanding at April 30, 2023 and October 31, 2022			—				—
	Common stock; $0.01 par value, 2 billion
		shares authorized; 295 million shares at April 30, 2023
		and 295 million shares at October 31, 2022, issued and outstanding			3				3
	Additional paid-in-capital				5,360				5,325
	Retained earnings				700				324
	Accumulated other comprehensive loss				(282	)			(347	)
		Total stockholders' equity			5,781				5,305
			Total liabilities and stockholders' equity	$	10,792			$	10,532
The preliminary balance sheet is estimated based on our current information.
Page 2

AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(In millions)
(Unaudited)
PRELIMINARY
					Six Months Ended
					April 30,				April 30,
					2023				2022
Cash flows from operating activities:
	Net income				$	654			$	557
Adjustments to reconcile net income to net cash provided by operating activities:
	Depreciation and amortization					138				164
	Share-based compensation					68				71
	Deferred taxes					(1	)			19
	Excess and obsolete inventory related charges					15				10
	Net loss on equity securities					14				62
	Change in fair value of contingent consideration					1				(25	)
	Other non-cash expense, net					2				9
	Changes in assets and liabilities:
		Accounts receivable, net				49				(108	)
		Inventory				(71	)			(124	)
		Accounts payable				(101	)			54
		Employee compensation and benefits				(110	)			(144	)
		Other assets and liabilities				36				(7	)
Net cash provided by operating activities (a)						694				538
Cash flows from investing activities:
	Investments in property, plant and equipment					(133	)			(139	)
	Payment to acquire equity securities					(1	)			(3	)
	Payment in exchange for convertible note					(5	)			(1	)
	Proceeds from sale of equity securities					5				6
	Proceeds from convertible note					4				—
	Acquisition of businesses and intangible assets, net of cash acquired					(51	)			(18	)
Net cash used in investing activities						(181	)			(155	)
Cash flows from financing activities:
	Issuance of common stock under employee stock plans					35				27
	Payment of taxes related to net share settlement of equity awards					(52	)			(64	)
	Payment of dividends					(133	)			(126	)
	Proceeds from revolving credit facility					175				—
	Repayment of revolving credit facility					(175	)			—
	Proceeds from issuance of commercial paper					1,412				575
	Repayment of commercial paper					(1,447	)			(400	)
	Payment for contingent consideration					(62	)			—
	Payments for repurchase of common stock					(160	)			(681	)
Net cash used in financing activities						(407	)			(669	)
Effect of exchange rate movements						16				(16	)
Net increase (decrease) in cash, cash equivalents and restricted cash						122				(302	)
Cash, cash equivalents and restricted cash at beginning of period						1,056				1,490
Cash, cash equivalents and restricted cash at end of period					$	1,178			$	1,188
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheet:
	Cash and cash equivalents				$	1,175			$	1,186
	Restricted cash, included in other assets					3				2
	Total cash, cash equivalents and restricted cash				$	1,178			$	1,188
(a) Cash payments included in operating activities:
	Income tax paid, net of refunds received				$	128			$	134
	Interest payments, net of capitalized interest				$	44			$	40
The preliminary cash flow is estimated based on our current information.
Page 3

AGILENT TECHNOLOGIES, INC.
NON-GAAP NET INCOME AND DILUTED EPS RECONCILIATIONS
(In millions, except per share amounts)
(Unaudited)
PRELIMINARY
				Three Months Ended												Six Months Ended
				April 30,												April 30,
				2023					2022							2023					2022
				Net Income		Diluted EPS			Net Income			Diluted EPS				Net Income		Diluted EPS			Net Income			Diluted EPS
GAAP net income				$	302	$	1.02		$	274		$	0.91			$	654	$	2.20		$	557		$	1.84
	Non-GAAP adjustments:
		Intangible amortization			38		0.12			50			0.17				74		0.25			101			0.34
		Transformational initiatives			5		0.02			9			0.03				12		0.04			13			0.04
		Acquisition and integration costs			5		0.02			8			0.03				7		0.02			15			0.05
		Change in fair value of contingent consideration			—		—			(28	)		(0.09	)			1		—			(25	)		(0.08	)
		Business exit and divestiture costs			—		—			7			0.02				—		—			7			0.02
		Net loss on equity securities			4		0.01			16			0.05				16		0.06			61			0.20
		Other			8		0.03			—			—				11		0.04			—			—
		Adjustment for taxes (a)			15		0.05			4			0.01				8		0.03			(21	)		(0.07	)
Non-GAAP net income				$	377	$	1.27		$	340		$	1.13			$	783	$	2.64		$	708		$	2.34
(a) The adjustment for taxes excludes tax benefits that management believes are not directly related to on-going operations and which are either isolated, temporary or cannot be expected to occur again with any regularity or predictability such as windfall benefits on stock compensation and the impact of R&D capitalization under section 174 of the Tax Cuts and Jobs Act of 2017. For the three and six months ended April 30, 2023, management used a non-GAAP effective tax rate of 13.75%. For the three months ended April 30, 2022, management used a non-GAAP effective tax rate of 13.92%. For the six months ended April 30, 2022, management used a non-GAAP effective tax rate of 14.00%.
We provide non-GAAP net income and non-GAAP net income per share amounts in order to provide meaningful supplemental information regarding our operational performance and our prospects for the future. These supplemental measures exclude, among other things, charges related to amortization of intangibles, transformational initiatives, acquisition and integration costs, change in fair value of contingent consideration, business exit and divestiture costs and net loss on equity securities.
	Transformational initiatives include expenses associated with targeted cost reduction activities such as manufacturing transfers including costs to move manufacturing, small site consolidations, legal entity and other business reorganizations, insourcing or outsourcing of activities. Such costs may include move and relocation costs, one-time termination benefits and other one-time reorganization costs. Included in this category are also expenses associated with company programs to transform our product lifecycle management (PLM) system, human resources and financial systems.
	Acquisition and integration costs include all incremental expenses incurred to effect a business combination. Such acquisition costs may include advisory, legal, accounting, valuation, and other professional or consulting fees. Such integration costs may include expenses directly related to integration of business and facility operations, the transfer of assets and intellectual property, information technology systems and infrastructure and other employee-related costs.
	Change in fair value of contingent consideration represents changes in the fair value estimate of acquisition-related contingent consideration.
	Business exit and divestiture costs include costs associated with business divestitures.
	Net loss on equity securities relates to the realized and unrealized mark-to-market adjustments for our marketable and non-marketable equity securities.
	Other includes certain legal costs and settlements, environment compliance costs related to a prior acquisition and acceleration of share-based compensation expense in addition to other miscellaneous adjustments.
Our management uses non-GAAP measures to evaluate the performance of our core businesses, to estimate future core performance and to compensate employees. Since management finds this measure to be useful, we believe that our investors benefit from seeing our results “through the eyes” of management in addition to seeing our GAAP results. This information facilitates our management’s internal comparisons to our historical operating results as well as to the operating results of our competitors.
Our management recognizes that items such as amortization of intangibles can have a material impact on our cash flows and/or our net income. Our GAAP financial statements including our statement of cash flows portray those effects. Although we believe it is useful for investors to see core performance free of special items, investors should understand that the excluded items are actual expenses that may impact the cash available to us for other uses. To gain a complete picture of all effects on the company’s profit and loss from any and all events, management does (and investors should) rely upon the GAAP income statement. The non-GAAP numbers focus instead upon the core business of the company, which is only a subset, albeit a critical one, of the company’s performance.
Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.
The preliminary non-GAAP net income and diluted EPS reconciliation is estimated based on our current information.
Page 4

AGILENT TECHNOLOGIES, INC.
SEGMENT INFORMATION
(In millions, except where noted)
(Unaudited)
PRELIMINARY
Quarter-over-Quarter
Life Sciences and Applied Markets Group
		Q2'23				Q2'22
Revenue		$	968			$	896
Gross Margin, %			59.9	%			59.0	%
Income from Operations		$	264			$	228
Operating margin, %			27.3	%			25.5	%
Diagnostics and Genomics Group
		Q2'23				Q2'22
Revenue		$	362			$	358
Gross Margin, %			51.8	%			56.0	%
Income from Operations		$	73			$	91
Operating margin, %			20.2	%			25.5	%
Agilent CrossLab Group
		Q2'23				Q2'22
Revenue		$	387			$	353
Gross Margin, %			47.0	%			47.1	%
Income from Operations		$	103			$	87
Operating margin, %			26.6	%			24.6	%
Income from operations reflect the results of our reportable segments under Agilent's management reporting system which are not necessarily in conformity with GAAP financial measures. Income from operations of our reporting segments exclude, among other things, charges related to amortization of intangibles, transformational initiatives, acquisition and integration costs, change in fair value of contingent consideration and business exit and divestiture costs.
Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.
The preliminary segment information is estimated based on our current information.
Page 5

AGILENT TECHNOLOGIES, INC.
RECONCILIATIONS OF REVENUE BY SEGMENT
EXCLUDING ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE)
(in millions)
(Unaudited)
PRELIMINARY
	Year-over-Year
	GAAP
					Year-over-Year
GAAP Revenue by Segment	Q2'23		Q2'22		% Change
Life Sciences and Applied Markets Group	$	968	$	896	8.0%
Diagnostics and Genomics Group		362		358	1.1%
Agilent CrossLab Group		387		353	9.8%
Agilent	$	1,717	$	1,607	6.8%
	Non-GAAP (excluding Acquisitions & Divestitures)						Year-over-Year at Constant Currency (a)
					Year-over-Year		Year-over-Year	Percentage Point Impact from Currency		Current Quarter Currency Impact (b)
Non GAAP Revenue by Segment	Q2'23		Q2'22		% Change		% Change
Life Sciences and Applied Markets Group	$	965	$	896	7.6%		10.5%	-3 ppts		$	(25	)
Diagnostics and Genomics Group		362		358	1.1%		3.3%	-2 ppts			(8	)
Agilent CrossLab Group		387		353	9.8%		13.2%	-3 ppts			(12	)
Agilent (Core)	$	1,714	$	1,607	6.6%		9.5%	-3 ppts		$	(45	)
We compare the year-over-year change in revenue excluding the effect of recent acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business.
(a) The constant currency year-over-year growth percentage is calculated by recalculating all periods in the comparison period at the foreign currency exchange rates used for accounting during the last month of the current quarter and then using those revised values to calculate the year-over-year percentage change.
(b) The dollar impact from the current quarter currency impact is equal to the total year-over-year dollar change less the constant currency year-over-year change.
The preliminary reconciliation of GAAP revenue adjusted for recent acquisitions and divestitures and impact of currency is estimated based on our current information.
Page 6

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005975/en/

Investor Contact:

Parmeet Ahuja

+1 408-345-8948

parmeet_ahuja@agilent.com

Media Contact:

Tom Beermann

+1 408-553-2914

tom.beermann@agilent.com

Source: Agilent Technologies Inc.